Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114841) titled 'Amitinib in Combination with Radiotherapy for Slowly Progressing/Locally Progressive Stage IV NSCLC with EGFR Mutations: A Real-World Study' on Dec. 18, 2025.
Study Type: Observational study
Study Design:
Cross-sectional
Primary Sponsor: The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)
Condition:
non-small cell lung cancer
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2024-10-19
Target Sample Size: Non-small cell lung cancer patient group:23;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj...